Pharmaceutical manufacturers of Theophylline

Alembic Pharmaceuticals Limited is involved in manufacturing and marketing India Formulations, International Generics, and Active Pharmaceutical Ingredients with vertical integration capabilities. Headquartered in Vadodara, Gujarat, we derive a third of our revenue of over $600 million from the India market.

Arevipharma is a modern manufacturer of active pharmaceutical ingredients and complex fine chemicals. With our products, we contribute to the health of millions of people on all continents. We are manufacturing health!

Siegfried serves as your favored associate for comprehensive integrated pharmaceutical ingredient and drug product services with manufacturing capabilities globally. Our expertise is crucial for your venture throughout the entire lifespan. Our enthusiasm lies in creating and producing formulations. It is extraordinary for a provider of development and manufacturing services to possess such a blend of inherent technical expertise and knowledge. Pharmaceutical ingredient services entail Tailored Development and Outsourced Manufacturing for both active pharmaceutical ingredients (API) and intermediates, along with our own range of API (opiates and other regulated substances) and documentation featuring independent patented technologies. Clients utilizing our drug product services benefit from a wealth of inherited expertise in intricate oral drug delivery systems, including sterile filling, backed by in-house development, customer development and manufacturing, and a wide array of completed dosage form products. Enhancing chemical processes and formulations is our area of specialization. We collaborate closely with clients to innovate and enhance chemical processes, thus providing additional benefits and value. Siegfried operates at 11 locations globally, spanning both the Eastern and Western Hemispheres, with multi-purpose cGMP chemical manufacturing facilities in Zofingen, Switzerland; Pennsville, New Jersey, USA; Nantong, China; Minden, Germany; Saint-Vulbas, France; Evionnaz, Switzerland; and sites for manufacturing drug products in Zofingen, Switzerland; Malta; Hameln, Germany, Irvine, USA; Barberà del Vallès, Spain and El Masnou, Spain. Count on Siegfried as your preferred partner for more opportunities.

CSPC Pharmaceutical Group Limited ("CSPC") (Stock code: 1093.HK) is a leading pharmaceutical group in China. The Company has been listed on the Main Board of the Hong Kong Stock Exchange since 1994 and became a constituent stock of the Hang Sang Index in 2018 (the 1st constituent stock in the pharmaceutical sector since launch of the index). CSPC is currently also a constituent stock of the "Hang Seng Composite Index", "Hang Seng Healthcare Index", "Hang Seng SCHK Mainland China Healthcare Index", "Hang Seng Stock Connect Hong Kong Index", "Hang Seng China (Hong Kong-listed) 100 Index" and "Hang Seng China Enterprises Index". CSPC mainly owns two business segments of finished drugs and bulk drugs, with innovative drugs as the core development strategy. CSPC currently has a strong product portfolio in the therapeutic areas of nervous system disease, oncology, anti-infective and cardiovascular disease. Of which "NBP", "Domeisu", "Jinyouli", "Keaili" and "Xuanning" are the most popular innovative drug products in China. Bulk drug products include vitamin C, antibiotics and caffeine series. The manufacturing facilities of CSPC are mainly located in Shijiazhuang City, Hebei Province, China. CSPC has a international R&D team with R&D bases in Shijiazhuang, Shanghai, Beijing and the United States, focusing on the discovery, research and development of small molecule targeted drugs, nano-drugs, monoclonal antibody drugs, bispecific antibody drugs, antibody-drug conjugates and biological drugs in the immune field.

Shandong Xinhua was founded in 1943. After evolving for more than 75 years, it has established 5 manufacturing facilities, spanning an area of over 3 million square meters. The company has set up two international branches and employs over 5000 staff. Its business encompasses API, finished dosage formulation, pharmaceutical intermediates, and pharmaceutical commerce.

Zim offers innovative solutions for administering medications, focusing on enhancing patient convenience and compliance. The company utilizes its own advanced technologies, such as modified release and taste masking, to create and produce distinct pharmaceutical products. Their range includes oral solid dosage formulations and pre-formulations (PFI), encompassing tablets, capsules, dry syrups, pellets, granules, and orally disintegrating strips (ODS). Additionally, they provide services for site transfer/variation for sustained release tablets, oral disintegrating tablets, fast disintegrating capsules, and more.

Roche CustomBiotech offers an extensive array of products and services for the diagnostics, biotechnology, and pharmaceutical industries. Our range of offerings includes enzymes, coenzymes, substrates, PCR-based kits for rapid microbiological methods, as well as the Cedex HiRes and Cedex Bio HT Analyzers for monitoring cell growth and fermentation processes.

Hainan Poly Pharm. Co., Ltd. is a prominent publicly traded generic producer in China, specializing in injectable medications, solid oral formulations, and prefilled syringes. The facility for injectable products has been thoroughly examined and endorsed by USFDA, EDQM, WHO, and CFDA. Additionally, the oral formulation facility has been scrutinized and approved by EDQM. This year, our new facility for oral formulations is set to undergo inspections from EDQM and US FDA. Poly excels in maintaining a cGMP system and developing high-barrier formulations. You are cordially invited to visit us at booth 214.

It has fully utilized synthesis methods primarily based on chemical reactions and purification methods to produce active pharmaceutical ingredients, intermediates, experimental drugs, functional organic compounds, food additives, and more, establishing a strong position in the active pharmaceutical ingredients industry through its advanced technologies. To ensure the secure use of high-quality products, an advanced quality assurance system has been established and is currently managed, with ongoing efforts to maintain and enhance the system in line with specified quality policies.

Kores India Limited, Pharmaceuticals & Chemicals Division, is a top producer of APIs and Pharmaceutical Intermediates

The Bakul Group of enterprises, situated in Mumbai, India, are involved in the production and fabrication of premium Active Pharmaceutical Ingredients (APIs), Intermediates, and Speciality Chemicals. Since establishment in 1975, they have expanded to achieve global eminence in the field of xanthine chemistry. Their expertise lies in the production of APIs like Linagliptin, Pentoxifylline, Theobromine, Doxofylline, Caffeine, Pamabrom, and others.

For over 40 years, VALPHARMA has specialized in the production and contract manufacturing of modified release products in capsules (hard-soft) and tablets, utilizing proprietary technology, and distributing them to pharmaceutical companies globally. Its dedicated R&D Department creates numerous new modified release products annually with proprietary patents, altering dosage from three or more daily administrations to once or twice daily dosing, enhancing pharmaceutical effectiveness, and reducing adverse effects

Established in 1987, Jilin Shulan Synthetic Pharmaceutical Co.,Ltd is a nationally designated manufacturer of Caffeine. It stands as a prominent producer of chemical raw materials and food additives in China. The company's primary products include Caffeine, Theophylline, Aminophylline, and theobromine. Situated in Shulan City, Jilin Province, the company spans an area of 110,000 square meters.

Concordia Labs are a group of computer labs at Concordia University's engineering school, offering high-powered computers, specialized software, and equipment for students and researchers. They provide essential resources for academic and research projects.

Hebei Guangxiang Pharmaceutical Co., Ltd. is situated in the Biomedical Industrial Park of Bohai New Area, Cangzhou. This facility serves as a comprehensive manufacturing hub for bulk drugs, intermediate compounds, and biological pharmaceutical preparations. The Group has invested 3 billion yuan in its development, encompassing over 666,600 square meters. The production hardware and equipment have achieved an internationally advanced standard. The company aims to establish itself as a major domestic production base for raw materials with significant influence.